Pharmacokinetics in IBD: Ready for prime time?

Current Drug Targets

Volumn 15, Issue 11, 2014, Pages 1049-1055

  Roblin, Xavier ^a   Rinaudo, Melanie ^a   Sparrow, Miles Peter ^b   Moreau, Amelie ^a   Phelip, Jean Marc ^a   Genin, Christian ^a   Lamarque, Dominique ^c   Paul, Stephane ^a  

^a UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^b MONASH UNIVERSITY   (Australia)

^c HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Anti TNF treatment; Antibodies to anti TNF; Crohn s disease; Optimisation; Trough levels of anti TNF; Ulcerative colitis

Indexed keywords

ADALIMUMAB; ALBUMIN; C REACTIVE PROTEIN; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR; VEDOLIZUMAB;

ARTICLE; CROHN DISEASE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MONITORING; ENZYME LINKED IMMUNOSORBENT ASSAY; HEALING; HUMAN; IMMUNE DEFICIENCY; IMMUNOGENICITY; INFLAMMATORY BOWEL DISEASE; INFUSION RELATED REACTION; META ANALYSIS (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REMISSION; TREATMENT FAILURE; TREATMENT RESPONSE; ULCERATIVE COLITIS;

EID: 84924298672     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450115666140829153509     Document Type: Article

References (44)

1. Bendtzen K. Anti-TNF-α biotherapies: perspectives for evidencebased personalized medicine. Immunotherapy 2012; 4(11): 1167-79.
2. Peyrin-Biroulet L, Reinisch W, Colombel JF, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut 2014, 63: 88-95.
3. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
4. Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009; 137: 1250-1260; quiz 1520.
5. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65.
6. Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther 2011; 33: 987-95.
7. Ordas I, Feagan BG, Sandborn WJ. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol 2012; 10: 1079-1087; quiz e1085-1076.
8. Ordas I, Mould DR, Feagan BG, Sandborn WJ. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 2012; 91: 635-46.
9. Paul S, Del Tedesco E, Marotte H, et al. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis 2013; 19: 2568-76.
10. Vermeire S, Gabriels F, Ballet V. The effect of dose escalation on trough levels in patients who lost response to infliximab. Gut 2010, 59: A81.
11. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009; 137: 1628-40.
12. Roblin X, Marotte H, Rinaudo M, et al. Association Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients with Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2013.
13. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol 2013; 108: 40-47; quiz 48.
14. West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PC, van der Woude CJ. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther 2008; 28: 1122-6.
15. Ungar B, Chowers Y, Yavzori M, et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut 2014; 63(8): 1258-64.
16. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146: 85-95; quiz e14-85.
17. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-tosevere ulcerative colitis. Gastroenterology 2014; 146: 96-109 e101.
18. Van Moerkeroke W, Ackaert C, Compernolle G. High infliximab trough levels are associated with mucosal healing in Crohn's disease. Gastroenterology 2010; 5: S60.
19. O'Meara S, Nanda KS, Moss AC. Antibodies to Infliximab and Risk of Infusion Reactions in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis 2014; 20: 1-6.
20. Bortlik M, Duricova D, Malickova K. Infliximab trough levels may predict sustained response ton infliximab in patients with Crohn's disease: a single cohort study. J Crohn's & Colitis 2012; 6: S153.
21. Arias MVC, Drobne D. Importance of trough levels and antibodies on the long-term efficacy of infliximab therapy in ulcerative colitis. J Crohn's & Colitis 2012; 6: S5.
22. Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012; 142: 63-70 e65; quiz e31.
23. Ben-Horin S, Mazor Y, Yanai H, et al. The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD. Aliment Pharmacol Ther 2012; 35: 714-722.
24. Roblin X, Rinaudo M, Del Tedesco E, et al. Development of an algorithm incorporating pharmakinetics of adalimumab in IBD. In IMMI. Edited by. Nice; 2014.
25. Baert F, Drobne D, Gils A, et al. Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Re-initiation of Infliximab Therapy. Clin Gastroenterol Hepatol 2014; 12(9): 1474-81.
26. Afif W, Loftus EV, Jr., Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010, 105: 1133-9.
27. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-95.
28. Kopylov U, Mazor Y, Yavzori M, et al. Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of antiinfliximab antibodies. Inflamm Bowel Dis 2012, 18: 1628-33.
29. Imaeda H, Takahashi K, Fujimoto T, et al. Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease. J Gastroenterol 2014; 49(1): 100-9.
30. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 2006; 54: 3782-89.
31. Feagan B, Singh S., Lockton S. Novel infliximab and antibody to infliximab assays are predictive of disease activity in patients with crohn's disease. Gastroenterology 2012; 5: 505.
32. Paul S, Rinaudo M, Del Tedesco E. et al. Pharmacokinetics of Adalimumab in Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. Inflamm Bowel Dis 2014; 20: 1288-95.
33. Vande Casteele N, Buurman DJ, Sturkenboom MG, et al. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther 2012; 36: 765-71.
34. Vande Casteele N, Gils A, Singh S, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 2013; 108: 962-971.
35. Chiu YL, Rubin DT, Vermeire S, et al. Serum adalimumab concentration and clinical remission in patients with Crohn's disease. Inflamm Bowel Dis 2013; 19: 1112-22.
36. Velayos FS, Sheibani S, Lockton S, et al. Prevalence of antibodies to adalimumab (ATA) and correlation between ATA and low serum drug concentration on CRP and clinical symptoms in a prospective sample of IBD patients. In DDW 2013. Edited by Hepatology Ga. Orlando; 2013: 4-5. vol 9 (8).].
37. Leclerc M. P, S., and Roblin, X.: Cinétiques des ATI prédit la perte de réponse clinique au cours des MICI. In JFHOD. Edited by. Paris; 2014: P479.
38. Rinaudo M, Paul S, Del Tedesco E, et al. Corrélation entre le taux d'infliximab évalué par technique Elisa et la bioactivité de l'infliximab chez des patients atteints de la maladie de Crohn ou de rectocolite hémorragique. In JFHOD. Edited by. Paris; 2014.
39. Atreya R, Neumann H, Neufert C, et al. In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease. Nat Med 2014; 20: 313-8.
40. Vande Casteele N. Individualised infliximab regimen using therapeutic drug monitoring: a prospective controlled trough level adapted infliximab treatment trial (TAXIT). In UEGW 2013. Edited by: Journal of Crohn's and Colitis 2013: S6.
41. Sorrentino D, Paviotti A, Terrosu G, Avellini C, Geraci M, Zarifi D. Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease. Clin Gastroenterol Hepatol 2010; 8: 591-599 e591; quiz e578-599.
42. Velayos FS, Kahn JG, Sandborn WJ, Feagan BG. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol 2013; 11: 654-66.
43. Steenholdt C, Brynskov J, Thomsen OO, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut 2014; 63(6): 919-27.
44. Pariente B, Pineton de Chambrun G, Krzysiek R, et al. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 1199-206.